Mark Sculpher

41.0k total citations · 13 hit papers
361 papers, 27.3k citations indexed

About

Mark Sculpher is a scholar working on Economics and Econometrics, General Health Professions and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Mark Sculpher has authored 361 papers receiving a total of 27.3k indexed citations (citations by other indexed papers that have themselves been cited), including 193 papers in Economics and Econometrics, 100 papers in General Health Professions and 56 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Mark Sculpher's work include Health Systems, Economic Evaluations, Quality of Life (184 papers), Healthcare cost, quality, practices (69 papers) and Healthcare Policy and Management (58 papers). Mark Sculpher is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (184 papers), Healthcare cost, quality, practices (69 papers) and Healthcare Policy and Management (58 papers). Mark Sculpher collaborates with scholars based in United Kingdom, United States and Canada. Mark Sculpher's co-authors include Karl Claxton, Andrew Briggs, Elisabeth Fenwick, Andrea Manca, Martin Buxton, Neil Hawkins, Michael Drummond, Su Golder, Stephen Palmer and Michael Drummond and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Mark Sculpher

344 papers receiving 26.4k citations

Hit Papers

Decision Modelling For Health Economic Evaluation 1998 2026 2007 2016 2006 2016 1998 2001 1998 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Decision Modelling For Health Economic Evaluation
    2006 2.3k citations Andrew Briggs, Karl Claxton et al. profile →
  2. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
    2016 2.2k citations Peter J. Neumann, Mark Sculpher et al. profile →
  3. Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses.
    1998 857 citations Mark Sculpher, Andrew Briggs et al. PubMed profile →
  4. Representing uncertainty: the role of cost‐effectiveness acceptability curves
    2001 837 citations Karl Claxton, Mark Sculpher et al. profile →
  5. An Introduction to Markov Modelling for Economic Evaluation
    1998 707 citations Andrew Briggs, Mark Sculpher profile →
  6. Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility
    2004 695 citations Andrea Manca, Neil Hawkins et al. profile →
  7. Model Parameter Estimation and Uncertainty Analysis
    2012 629 citations Andrew Briggs, Mark Sculpher et al. profile →
  8. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research
    2016 574 citations Beth Woods, Paul Revill et al. profile →
  9. Review of guidelines for good practice in decision-analytic modelling in health technology assessment
    2004 528 citations Mark Sculpher, Karl Claxton et al. Health Technology Assessment profile →
  10. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
    2015 511 citations Karl Claxton, Marta Soares et al. Health Technology Assessment profile →
  11. Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6
    2012 495 citations Andrew Briggs, Mark Sculpher et al. profile →
  12. Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report
    2009 388 citations Mark Sculpher et al. profile →
  13. Economic analysis of the prevalence and clinical and economic burden of medication error in England
    2020 207 citations Rachel Elliott, Dina Janković et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Sculpher United Kingdom 77 10.6k 5.6k 4.4k 3.2k 3.0k 361 27.3k
Andrew Briggs United Kingdom 81 11.5k 1.1× 5.8k 1.0× 4.6k 1.0× 3.0k 0.9× 4.4k 1.5× 422 31.9k
Milton C. Weinstein United States 94 11.8k 1.1× 6.7k 1.2× 4.6k 1.1× 3.3k 1.0× 6.2k 2.1× 354 33.8k
Robert H. Brook United States 74 8.4k 0.8× 10.3k 1.8× 3.0k 0.7× 2.7k 0.9× 2.1k 0.7× 493 26.4k
E. John Orav United States 95 4.8k 0.5× 8.0k 1.4× 4.8k 1.1× 7.7k 2.4× 3.1k 1.0× 446 33.5k
John Brazier United Kingdom 97 15.1k 1.4× 9.0k 1.6× 5.0k 1.1× 1.5k 0.5× 6.1k 2.1× 557 39.3k
Miguel A. Hernán United States 93 5.8k 0.5× 2.6k 0.5× 2.9k 0.7× 2.8k 0.9× 4.4k 1.5× 313 42.2k
John Z. Ayanian United States 87 7.3k 0.7× 7.8k 1.4× 3.1k 0.7× 3.2k 1.0× 2.5k 0.8× 355 26.1k
Alastair Gray United Kingdom 72 4.7k 0.4× 3.7k 0.7× 4.3k 1.0× 2.6k 0.8× 3.0k 1.0× 343 19.1k
Peter J. Neumann United States 72 9.4k 0.9× 5.0k 0.9× 1.9k 0.4× 968 0.3× 1.9k 0.6× 367 20.4k
Thérèse A. Stukel Canada 75 5.0k 0.5× 4.7k 0.8× 7.0k 1.6× 3.9k 1.2× 3.4k 1.1× 307 26.5k

Countries citing papers authored by Mark Sculpher

Since Specialization
Citations

This map shows the geographic impact of Mark Sculpher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sculpher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sculpher more than expected).

Fields of papers citing papers by Mark Sculpher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Sculpher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sculpher. The network helps show where Mark Sculpher may publish in the future.

Co-authorship network of co-authors of Mark Sculpher

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Sculpher. A scholar is included among the top collaborators of Mark Sculpher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Sculpher. Mark Sculpher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Perelman, Julian, et al.. (2026). Revised methods guide for economic evaluation studies of health technologies in Portugal. International Journal of Technology Assessment in Health Care. 42(1). e11–e11.
2.
Candore, Gianmario, Claire Martin, Ashley Lloyd, et al.. (2025). FRAME: Framework for Real‐World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness – An Evaluation of Regulatory and Health Technology Assessment Decision Making. Clinical Pharmacology & Therapeutics. 118(3). 649–661. 1 indexed citations
3.
Bowlus, Christopher L., Cynthia Levy, Kris V. Kowdley, et al.. (2025). Development of the natural history component of an early economic model for primary sclerosing cholangitis. Orphanet Journal of Rare Diseases. 20(1). 133–133.
4.
Woods, Beth, Dina Janković, Benjamin Kearns, et al.. (2024). Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Health Technology Assessment. 28(28). 1–238. 3 indexed citations
5.
Ochalek, Jessica, Rita Faria, Joydeepa Darlong, et al.. (2023). Economic evaluation of self-help group interventions for health in LMICs: a scoping review. Health Policy and Planning. 38(9). 1033–1049.
6.
Davies, Heather, Marta Soares, Beth Woods, et al.. (2023). Developing a Modeling Framework for Quantifying the Health and Cost Implications of Antibiotic Resistance for Surgical Procedures. MDM Policy & Practice. 8(1). 107899637–107899637. 2 indexed citations
7.
Mohan, Sakshi, et al.. (2022). Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates. PLoS neglected tropical diseases. 16(6). e0010471–e0010471. 23 indexed citations
8.
Cohen, Joshua T., Kalipso Chalkidou, Yot Teerawattananon, et al.. (2019). Adherence to the iDSI reference case among published cost-per-DALY averted studies. PLoS ONE. 14(5). e0205633–e0205633. 27 indexed citations
9.
Spackman, Eldon, Sebastian Hinde, Laura Bojke, Katherine Payne, & Mark Sculpher. (2017). Using Cost-Effectiveness Analysis to Quantify the Value of Genomic-Based Diagnostic Tests: Recommendations for Practice and Research. Genetic Testing and Molecular Biomarkers. 21(12). 705–716. 8 indexed citations
10.
Duarte, Ana, Jane Walker, Simon Walker, et al.. (2015). Cost-effectiveness of integrated collaborative care for comorbid major depression in patients with cancer. Journal of Psychosomatic Research. 79(6). 465–470. 37 indexed citations
11.
Spackman, Eldon, Stewart Richmond, Mark Sculpher, et al.. (2014). Cost-Effectiveness Analysis of Acupuncture, Counselling and Usual Care in Treating Patients with Depression: The Results of the ACUDep Trial. PLoS ONE. 9(11). e113726–e113726. 25 indexed citations
12.
Walker, Simon, Jane Walker, Gerry Richardson, et al.. (2013). Cost-effectiveness of combining systematic identification and treatment of co-morbid major depression for people with chronic diseases: the example of cancer. Psychological Medicine. 44(7). 1451–1460. 24 indexed citations
13.
Chambers, Duncan, Gillian Worthy, Lindsey Myers, et al.. (2010). Glycopeptide vs. Non-Glycopeptide Antibiotics for Prophylaxis of Surgical Site Infections: A Systematic Review. Surgical Infections. 11(5). 455–462. 20 indexed citations
14.
Newman, Stanton, Debbie Cooke, Angela Casbard, et al.. (2009). A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE). Health Technology Assessment. 13(28). iii–iv, ix. 16 indexed citations
15.
Briggs, Andrew, Karl Claxton, & Mark Sculpher. (2006). Decision Modelling For Health Economic Evaluation. 2349 indexed citations breakdown →
16.
17.
18.
Wellwood, J M, Mark Sculpher, David L. Stoker, et al.. (1998). Randomised controlled trial of laparoscopic versus open mesh repair for inguinal hernia: outcome and cost. BMJ. 317(7151). 103–110. 226 indexed citations
19.
Kohner, Eva M., Justin M. Andrews, Frances M. Brown, et al.. (1996). Report of the Visual Handicap Group.. PubMed. 13(9 Suppl 4). S13–26. 9 indexed citations
20.
Sculpher, Mark, Martin Buxton, Paul T. Seed, et al.. (1994). Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. The Lancet. 344(8927). 927–930. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew Briggs Breakdown of academic impact, for papers by Milton C. Weinstein Breakdown of academic impact, for papers by Robert H. Brook Breakdown of academic impact, for papers by E. John Orav Breakdown of academic impact, for papers by John Brazier Breakdown of academic impact, for papers by Miguel A. Hernán Breakdown of academic impact, for papers by John Z. Ayanian Breakdown of academic impact, for papers by Alastair Gray Breakdown of academic impact, for papers by Peter J. Neumann Breakdown of academic impact, for papers by Thérèse A. Stukel
Rankless by CCL
2026